(5Z)-5-[[3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (5Z)-5-[[3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)-4-(trifluoromethoxy)phenyl]methylidene]-1,3-thiazolidine-2,4-dione
• 化学式: C₂₆H₂₆F₃NO₃S
• 分子量: 489.6
• InChiKey: ZCFXFIHRHWRKAY-MTJSOVHGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.5
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes
  申请人：Lagu Bharat

  公开号：US20070078129A1

  公开（公告）日：2007-04-05

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating RXR mediated disorders. More particularly, the compounds of the present invention are RXR agonists useful for treating RXR mediated disorders.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体及其衍生物以及用于治疗RXR介导的疾病。更具体地说，本发明的化合物是RXR激动剂，可用于治疗RXR介导的疾病。
• [EN] BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS<br/>[FR] COMPOSÉS HÉTÉROARYLES BICYCLIQUES EN TANT QUE MODULATEURS DE GPR119
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011140160A1

  公开（公告）日：2011-11-10

  Novel compounds of structure Formula I: or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein A, D, Di, E, J, L, n, Q, R2 and R4 are defined herein, are provided which are GPR119 G protein- coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  结构式I的新化合物：或其对映体、二对映体、互变异构体、前药或盐，其中A、D、Di、E、J、L、n、Q、R2和R4在此处被定义，提供了这些化合物是GPR119 G蛋白偶联受体调节剂。GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病的进展方面是有用的。因此，本公开还涉及包含这些新化合物的组合物和使用任何这些新化合物或包含任何这些新化合物的组合物治疗与GPR119 G蛋白偶联受体活性相关的疾病或症状的方法。
• Substituted Dihydroisoindolones As Allosteric Modulators of Glucokinase
  申请人：Dudash Joseph

  公开号：US20070099930A1

  公开（公告）日：2007-05-03

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating glucokinase mediated disorders. More particularly, the compounds of the present invention are glucokinase modulators useful for treating disorders including, but not limited to, type II diabetes.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体和衍生物，以及用于治疗葡萄糖激酶介导的疾病。更具体地说，本发明的化合物是葡萄糖激酶调节剂，可用于治疗包括但不限于II型糖尿病在内的疾病。
• [EN] NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR TGR5 SOUS FORME D'HÉTÉROARYLES BICYCLIQUES CONTENANT DE L'AZOTE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012149236A1

  公开（公告）日：2012-11-01

  Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  公式I的新化合物：或其对映体、二对映体、互变异构体、前药或盐，其中m、Q、T、U、V、环A、X、Y、R3、R4、R4a、R5a、R5b、R5c、R5d、R5e、R6a、R6b和R6c在此定义，提供了TGR5 G蛋白偶联受体调节剂。TGR5 G蛋白偶联受体调节剂在治疗、预防或减缓需要TGR5 G蛋白偶联受体调节剂治疗的疾病的进展方面是有用的。因此，本公开还涉及包含这些新化合物的组合物以及使用任何这些新化合物或包含任何这类新化合物的组合物治疗与TGR5 G蛋白偶联受体活性相关的疾病或症状的方法。
• Dihydroisoindolones As Allosteric Modulators Of Glucokinase
  申请人：Bian Hiayan

  公开号：US20070099936A1

  公开（公告）日：2007-05-03

  The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating glucokinase mediated disorders. More particularly, the compounds of the present invention are glucokinase modulators useful for treating disorders including, but not limited to, type II diabetes.

  本发明涉及式(I)的化合物，制备这些化合物的方法，组合物，中间体和衍生物，以及用于治疗葡萄糖激酶介导的疾病。更具体地，本发明的化合物是葡萄糖激酶调节剂，可用于治疗包括但不限于II型糖尿病在内的疾病。